STOCK TITAN

Equillium - EQ STOCK NEWS

Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.

Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.

Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.

Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.

Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ) announced Q3 2023 financial results, highlighting $46.3 million in cash, clinical study updates, and upcoming milestones. The company's cash runway is expected to extend into 2025, with a focus on creating shareholder value. Revenue was $8.9 million, R&D expenses were $9.0 million, and net loss was $3.7 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
Equillium, Inc. presented data from the EQUALISE study at the annual meeting of the American Society of Nephrology. The data showed high response rates and rapid reduction in urine protein creatinine ratio (UPCR) in lupus nephritis patients when itolizumab was added to the treatment. The study demonstrated both early and deep reductions in proteinuria, indicating potential long-term benefits for patients. The study also highlighted the favorable safety and tolerability profile of itolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Persephone Biosciences appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
management
Rhea-AI Summary
Equillium announces enrollment completion for Phase 1b study in lupus nephritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Equillium Inc. announces presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor in development to target IL-15 and IL-21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
-
News
Rhea-AI Summary
Equillium, Inc. will host a virtual analyst and investor day on October 16, 2023, providing a review of its pipeline and a focus on its lead asset, EQ101, currently in a Phase 2 clinical trial for alopecia areata.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Equillium, Inc. will present at the JonesTrading 2023 Healthcare Summit, discussing industry trends and strategic alliances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences
-
Rhea-AI Summary
Equillium, Inc. to present at Cantor Fitzgerald Global Healthcare Conference and LD Micro Main Event Conference. Management will provide an overview of the Company’s multi-cytokine inhibitor platform and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Summary
Equillium, Inc. to host investor meetings at Wells Fargo Healthcare Conference and present at H.C. Wainwright 25th Annual Global Investor Conference. Management to provide overview of EQ101 and EQ102 treatments, as well as itolizumab development. Webcast access available for H.C. Wainwright conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
Equillium

Nasdaq:EQ

EQ Rankings

EQ Stock Data

16.88M
22.77M
36.15%
19.42%
1.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA